Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Income Statement
Quarterly Data

Paying users area

The data is hidden behind: . Unhide it.

  • Get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99, or

  • get full access to the entire website for at least 3 months from $62.19.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Regeneron Pharmaceuticals Inc., consolidated income statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net product sales
Collaboration revenue
Other revenue
Revenues
Cost of goods sold
Cost of collaboration and contract manufacturing
Cost of revenues
Gross profit
Research and development
Acquired in-process research and development
Selling, general, and administrative
Other operating income (expense), net
Income from operations
Other income (expense), net
Interest expense
Other income (expense)
Income before income taxes
Income tax expense
Net income

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Revenues Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Regeneron Pharmaceuticals Inc. revenues increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Income from operations The net result for the period of deducting operating expenses from operating revenues. Regeneron Pharmaceuticals Inc. income from operations increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Regeneron Pharmaceuticals Inc. income before income taxes increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Net income The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Regeneron Pharmaceuticals Inc. net income increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.